We then evaluated the protein level of TET2 via immunohistochemistry (IHC) in two different cohorts, a CRC tissue array (Shanghai-Taizhou cohort, 194 patients) and CRC paraffin sections (Guangzhou cohort, 186 patients). This evidence concerns the gene TET2 and colorectal carcinoma.